| Trial ID: | L5484 |
| Source ID: | NCT01486875
|
| Associated Drug: |
Biphasic Insulin Aspart 30
|
| Title: |
Observational Study of Safety of NovoMix® 30 Treatment for Type 2 Diabetes
|
| Acronym: |
Start
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes|Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: biphasic insulin aspart 30
|
| Outcome Measures: |
Primary: Incidence of serious adverse drug reactions (SADRs), Week 26|Incidence of major hypoglycaemic events, Week 26 | Secondary: Number of all hypoglycaemic events, In the 4 weeks prior to week 12 and week 26, respectively|HbA1c (glycosylated haemoglobin A1c), Week 26|Fasting Plasma Glucose (FPG), Week 26
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
1155
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2006-01
|
| Completion Date: |
2008-01
|
| Results First Posted: |
|
| Last Update Posted: |
2017-01-06
|
| Locations: |
Novo Nordisk Investigational Site, Lund, 221 85, Sweden
|
| URL: |
https://clinicaltrials.gov/show/NCT01486875
|
